Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation.
Strom Halden TA, Asberg A, et al.Nephrology Dialysis Transplantation 2014; 29(4): 926-933.
Aims
To investigate the effectiveness of sitagliptin treatment on insulin secretion in long term stable kidney transplant recipients with new-onset diabetes after transplantation (NODAT).
Interventions
Patients were randomised to receive sitagliptin once daily for four weeks followed by four weeks with no sitagliptin. The other study group received no sitagliptin for four week s followed by four weeks of sitagliptin treatment.
Participants
19 long-term stable renal transplant recipients with NODAT.
Outcomes
The outcomes of the study included the changes of insulin secretion against baseline, glucose metabolism, body mass index and blood pressure, endothelial function and changes in the selected plasma markers of cardiovascular risk.
Follow-up
2 weeks
CET Conclusions
This is a small but interesting crossover study designed to investigate the efficacy and safety of sitagliptin treatment in stable renal transplant patients with NODAT. Sitagliptin is an oral agent which increases pancreatic insulin secretion and decreases glucagon release. Insulin secretion was increased and fasting and post prandial plasma glucose was also reduced. The short term treatment was well tolerated and there were no safety problems but the period of treatment was quite short. Certainly this agent is worthy of further study in the renal transplant population.
Data analysis
Per protocol analysis
Trial registration
ClinicalTrials.gov NCT - 00740363